Meta-analysis for changes in other outcomes from baseline to the last available follow-up
| Parameter | Number of patients (number of studies) | Estimate (95% CI)* | I2 (%) | P value |
| Changes in patients using FGM | ||||
| Time in range (70–180 mg/dL) (hours/day) | 343 (3) | 0.55 (−0.17 to 1.26) | 48 | 0.14 |
| Time above 180 mg/dL (hours/day) | 343 (3) | 0.19 (−0.90 to 1.29) | 73 | 0.73 |
| Time below 70 mg/dL (hours/day) | 621 (4) | −0.60 (−1.18 to −0.03) | 90 | 0.04 |
| Hypoglycemic events (n/day) | 597 (7) | −0.04 (−0.23 to 0.15) | 91 | 0.67 |
| SMBG measurements (n/day) | 401 (5) | −4.55 (−5.74 to −3.35) | 95 | <0.001 |
| Total daily insulin dose (IU/day) | 517 (6) | −1.22 (−4.29 to 1.86) | 0 | 0.44 |
| Differences in changes in patients using FGM versus patients using SMBG | ||||
| SMBG measurements (n/day) | 832 (4) | −3.76 (−4.79 to −2.72) | 86 | <0.001 |
| Total daily insulin dose (IU/day) | 498 (3) | 0.23 (−1.34 to 1.80) | 0 | 0.77 |
| Discontinuation | 564 (3) | 0.42 (0.25 to 0.71) | 0 | 0.001 |
*Data are expressed as relative risk for discontinuation and as weighted mean differences for the other outcomes.
FGM, flash glucose monitoring; SMBG, self-monitoring of blood glucose.